Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.

Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition

Amgen

Cigna

Elevance Health Inc

Humana

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp. NASDAQ: PODD and Cigna Group NYSE: CI.

5 top healthcare stocks for earnings growth in 2024

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Report Fourth Quarter and Year-End 2023 Financial Results.

Incyte to Report Fourth Quarter and Year-End 2023 Financial Results

Exelixis

Pfizer

Investing in biopharmaceutical stocks is a lesson in quantity and quality. That is, the best pharma stocks have products that are commercially available.

3 Pharma Stocks Could Be the Pills Your Portfolio Needs

Insulet

UnitedHealth Group

Health Care Select Sector SPDR Fund

Zoetis

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference.

Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Allstate

Eli Lilly

Merck

Moderna

Viatris

The calendar just flipped to 2024 — and investors already have their favorite S&P 500 stocks. And none of them are the Big Tech giants that dominated.

7 Stocks Are Taking Off Already — And The Year Just Started

Alnylam Pharmaceuticals

argenx

Blueprint Medicines

Genmab - ADR

Seagen

Sarepta Therapeutics

Alexion Pharma

Celgene

Horizon Pharma

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

5 Biotech Acquisition Targets To Accumulate In 2024

Bio-Rad Laboratories

Bristol-Myers

After an abysmal year for healthcare stocks, Wall Street is upbeat on Cigna, Humana, Bristol Myers, and three others.

6 Stock Picks in Healthcare for 2024

Kiniksa Pharmaceuticals Ltd

Neurocrine Biosciences

As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company's making these strides have incredible results to show for it.

The 3 Most Undervalued Biotech Stocks to Buy in December

Shares of the biopharmaceutical company are on pace for their best day in more than six years.

Incyte Stock Is the S&P 500's Top Performer. Here's Why It's Surging.

WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)---- $INCY--Incyte and Syndax Present Additional Data from AGAVE-201 Trial at ASH Plenary Showing Axatilimab Efficacy Including Durable Responses in Chronic GVHD.

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?

CRISPR Therapeutics

Shockwave Medical

When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical trials, as companies with early stage drugs are too risky for me.

3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024

BioNTech SE

Corcept Therapeutics

Halozyme Therapeutics

Regeneron Pharmaceuticals

Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to march to its own beat, the underlying innovation may offer an alternative upside pathway.

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting.

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.

Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates

Incyte Corporation (NASDAQ:INCY ) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Relations Herve Hoppenot - President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manager, North America Pablo Cagnoni - President and Head of Research and Development Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Leonid Timashev - RBC Capital Markets David Lebowitz - Citigroup Inc. Jessica Fye - JPMorgan Chase & Co. Marc Frahm - TD Cowen Gospel Enyindah-Asonye - Morgan Stanley Matthew Phipps - William Blair & Co. Paul Jeng - Guggenheim Securities, LLC Mara Goldstein - Mizuho Securities Andrew Berens - SVB Securities Reni Benjamin - JMP Securities Operator Hello, and welcome to the Incyte Third Quarter Earnings Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.

Incyte Corporation (INCY) Q3 2023 Earnings Call Transcript

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakafi.

Drugmaker Incyte's quarterly profit beats on lower costs

Incyte (INCY) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.60 per share a year ago.

Incyte (INCY) Surpasses Q3 Earnings Estimates

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs.

Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023.

Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023

Incyte's stock has declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Despite the decline, Incyte reported strong financial performance with a 25% increase in net product revenues in Q2 2023 and revised guidance for its flagship product, Jakafi. Incyte's drug pipeline and future prospects include promising candidates in various stages of development for the treatment of cancer and inflammatory diseases, positioning the company for long-term growth.

Incyte: One Of The Most Undervalued Pharmaceuticals

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023.

News for Incyte Stock (INCY)